NL2030433B1 - Shrna lentivirus for inhibiting the expression of long non-coding rna malat1 and use thereof - Google Patents

Shrna lentivirus for inhibiting the expression of long non-coding rna malat1 and use thereof Download PDF

Info

Publication number
NL2030433B1
NL2030433B1 NL2030433A NL2030433A NL2030433B1 NL 2030433 B1 NL2030433 B1 NL 2030433B1 NL 2030433 A NL2030433 A NL 2030433A NL 2030433 A NL2030433 A NL 2030433A NL 2030433 B1 NL2030433 B1 NL 2030433B1
Authority
NL
Netherlands
Prior art keywords
malat1
expression
shrna
inhibiting
cells
Prior art date
Application number
NL2030433A
Other languages
English (en)
Dutch (nl)
Inventor
Wang Ying
Qian Lingjia
Xie Fang
Wang Xue
Zhao Yun
Original Assignee
Acad Of Military Medical Sciences Acad Of Military Science Of Chinese Pla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acad Of Military Medical Sciences Acad Of Military Science Of Chinese Pla filed Critical Acad Of Military Medical Sciences Acad Of Military Science Of Chinese Pla
Application granted granted Critical
Publication of NL2030433B1 publication Critical patent/NL2030433B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NL2030433A 2021-09-06 2022-01-05 Shrna lentivirus for inhibiting the expression of long non-coding rna malat1 and use thereof NL2030433B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111038413.5A CN113584037A (zh) 2021-09-06 2021-09-06 抑制长链非编码RNA MALAT1表达的shRNA慢病毒及其应用

Publications (1)

Publication Number Publication Date
NL2030433B1 true NL2030433B1 (en) 2023-03-21

Family

ID=78241247

Family Applications (1)

Application Number Title Priority Date Filing Date
NL2030433A NL2030433B1 (en) 2021-09-06 2022-01-05 Shrna lentivirus for inhibiting the expression of long non-coding rna malat1 and use thereof

Country Status (2)

Country Link
CN (1) CN113584037A (zh)
NL (1) NL2030433B1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114480309B (zh) * 2022-02-23 2023-06-06 中国人民解放军军事科学院军事医学研究院 抑制ALKBH1表达的shRNA慢病毒及其制备和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021035128A1 (en) * 2019-08-21 2021-02-25 H. Lee Moffitt Cancer Center And Research Institute Inc. Compositions and methods for treating chronic myelomonocytic leukemia

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CAO DING-WEN ET AL: "The lncRNA Malat1 functions as a ceRNA to contribute to berberine-mediated inhibition of HMGB1 by sponging miR-181c-5p in poststroke inflammation", ACTA PHARMACOLOGICA SINICA, NATURE PUBLISHING GROUP, GB, vol. 41, no. 1, 20 August 2019 (2019-08-20), pages 22 - 33, XP036976323, ISSN: 1671-4083, [retrieved on 20190820], DOI: 10.1038/S41401-019-0284-Y *
HUI LIU ET AL: "Down-regulation of long non-coding RNA MALAT1 by RNA interference inhibits proliferation and induces apoptosis in multiple myeloma", CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, WILEY-BLACKWELL PUBLISHING ASIA, AU, vol. 44, no. 10, 24 August 2017 (2017-08-24), pages 1032 - 1041, XP071596072, ISSN: 0305-1870, DOI: 10.1111/1440-1681.12804 *
SHANG JIN-LIN ET AL: "Cognitive improvement following ischemia/reperfusion injury induced by voluntary running-wheel exercise is associated with LncMALAT1-mediated apoptosis inhibition", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 12 February 2018 (2018-02-12), GR, XP055942126, ISSN: 1107-3756, DOI: 10.3892/ijmm.2018.3484 *
ZHANG BIN ET AL: "Identification and Characterization of a Class of MALAT1-like Genomic Loci", CELL REPORTS, vol. 19, no. 8, 1 May 2017 (2017-05-01), US, pages 1723 - 1738, XP055941885, ISSN: 2211-1247, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505346/pdf/nihms875556.pdf> DOI: 10.1016/j.celrep.2017.05.006 *

Also Published As

Publication number Publication date
CN113584037A (zh) 2021-11-02

Similar Documents

Publication Publication Date Title
CN105960413A (zh) 人工dna-结合蛋白及其用途
CN109641064A (zh) 非整合病毒递送系统及其相关方法
EP3935152B1 (en) Induced photoreceptor cells and methods for their production
US10925976B2 (en) Smooth muscle specific inhibition for anti-restenotic therapy
WO2014111876A2 (en) Modulation of mitophagy and use thereof
NL2030433B1 (en) Shrna lentivirus for inhibiting the expression of long non-coding rna malat1 and use thereof
Terada et al. Sumoylation controls retinal progenitor proliferation by repressing cell cycle exit in Xenopus laevis
CN109576227B (zh) 一种基于荧光素酶报告病毒的自噬细胞系构建方法
Jin et al. Effect of miR-497 on myocardial cell apoptosis in rats with myocardial ischemia/reperfusion through the MAPK/ERK signaling pathway.
CN110129319B (zh) 一种PRALR的siRNA及其用途
CN110066870B (zh) hsa-miR-382-5p在制备诊断视网膜变性疾病的试剂盒中的应用
CN114480309B (zh) 抑制ALKBH1表达的shRNA慢病毒及其制备和应用
CN113121667B (zh) 一种细胞膜成孔蛋白LjGSDM及其表达与应用
CN113403280B (zh) 一种靶向kgf启动子的间充质干细胞治疗急性肺损伤筛选模型
CN103667431B (zh) 一种人ccch型锌指蛋白表达基因的用途及其相关药物
CN104826130B (zh) Msx3基因特异诱导小胶质细胞选择性极化的方法及其应用
CN104368012B (zh) 人rpl34基因的用途及其相关药物
LU501763B1 (en) SMALL INTERFERING RNAs (siRNAs) FOR INTERFERING WITH ZINC FINGER PROTEIN 24 (ZNF24) GENE EXPRESSION AND USE THEREOF IN INHIBITING CELL PROLIFERATION AND MIGRATION
CN111789957B (zh) 敲低lncBCAS1-4_1细胞株与活性维生素D联用在制备抗肿瘤药物中的应用
CN110129334B (zh) IiWRKY34在调控菘蓝木脂素生物合成和抗逆胁迫反应中的应用
CN114457045B (zh) 抑制Slc2a1的RNAi腺相关病毒及其制备和应用
Maritato et al. A DNA base-specific sequence interposed between CRX and NRL contributes to RHODOPSIN expression
CN101502659A (zh) Krüppel样转录因子4的新用途
Pan et al. Binding of LncRNA-DACH1 to dystrophin impairs the membrane trafficking of Nav1. 5 protein and increases ventricular arrhythmia susceptibility
Guadagnino Exploring miRNAs as Modulators in Retinal Degeneration: Potential Therapeutic Tools for Inherited Retinal Dystrophies